GlassScriptPhysician profile
Shea M Eckardt
NPI 1730363912
$5,090.72
in general payments reported to CMS, 2019-2025
43 companies · $781 in 2025
The $781 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,229 · 2020: $596 · 2021: $175 · 2022: $380 · 2023: $873 · 2024: $1,057 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,525 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,525.16 |
| Education | $185.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,111.28 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $592.02 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Actelion Pharmaceuticals US, INC. | $412.54 | 2020-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.61 | 2019-2025 | Ofev, Stiolto Respimat |
| Insmed, INC. | $200.16 | 2019-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $184.27 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Takeda Pharmaceuticals U.S.A., INC. | $165.20 | 2023-2025 | Glassia |
| Genzyme Corporation | $140.48 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.26 | 2019-2025 | |
| Amgen INC. | $130.47 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $128.56 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $127.84 | 2024-2025 | Winrevair, Keytruda |
| Grifols USA, LLC | $108.06 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Mylan Specialty L.P. | $107.27 | 2019-2020 | |
| Harmony Biosciences LLC | $104.79 | 2020-2024 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shea Eckardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.